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The opportunity for total joint arthroplasty (TJA) in patients with chronic infectious liver disease is rapidly
expanding. This is the product of both superior survival of chronic hepatitis patients, evolving implant
technologies, and improvement of techniques in TJA. Unfortunately, treating this group of patients is not
without signiﬁcant challenges that can stem from both intrahepatic and extrahepatic clinical manifesta-
tions.Moreover,many subclinical changes occur in this cohort that can alter hemostasis,woundhealing, and
infection risk even in the asymptomatic patient. In this review, we discuss the various clinical presentations
of chronic infectious liver disease and summarize the relevant literature involving total joint arthroplasty for
this population. Hopefully, through appropriate patient selection and perioperative optimization, treating
surgeons should see continued improvement in outcomes for patients with chronic infectious liver disease.
Copyright © 2016 Published by Elsevier Inc. on behalf of American Association of Hip and Knee Surgeons.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction months previously, and the right TKAwas performed 3 years and 6Medical advances in recent years have improved the morbidity
and mortality of many chronic conditions. Chronic infectious liver
conditions are nowassociatedwith superior survival outcomes, and
as such, garner increasedattention fromcareproviders as challenges
associated with increased longevity are encountered [1,2].
Technological advances in techniques andmaterials of total joint
arthroplasty (TJA) have allowed for longer implant survival and the
ability to treat younger patients [3e5]. This convergence has
generated an overlap between chronic infectious liver disease pa-
tients and TJA that mandates the attention of orthopedic surgeons
and collaborating providers caring for this challenging population.
Case history
A 57 year-old male patient was referred for evaluation. He was
status post bilateral TKA. The left TKAwas performed 3 years and 11closed potential or pertinent
ent, either direct or indirect,
the biomedical ﬁeld which
rest with this work. For full
6/j.artd.2015.07.001.
d, CA 94305, USA. Tel.: (650)
c. on behalf of American Associatio
d/4.0/).months previously. The patient had been experiencing worsening
pain in the left knee, now rated 10/10, and was unable to weight
bear on the knee for the past 6 weeks, requiring a power scooter for
general mobility. Images at initial presentation are shown in Fig. 1.
Examination at that time demonstrated an obtunded patient
with a BMI of 35.9. He had well healed incisions, with a symmetric
range of motion from 20 to 100. There was a mild effusion and
tenderness at the femur and tibial aspects of the left knee, with
inability to bear weight on the limb. Lab values included WBC 4.2k,
CRP 1.3, Hgb 9.3, and a platelet count of 76. Two recent knee as-
pirations performed at our center demonstrated no evidence of
bacteria on the gram stains or ﬁnal cultures. Synovial WBC count
was initially 720 with 60% neutrophils, and the second aspirate
performed four months later revealed 1980 WBC with 83%
neutrophils.
During the initial examination, the patient was frankly dis-
oriented and incoherent and was spoken for by his wife, who
advocated for him to seek surgical intervention for his knee pain.
He had a well-established history of viral hepatitis with cirrhosis,
and had been admitted for hepatic encephalopathy 4 to 5 times
over the past 2 years at various local hospitals. After a brief or-
thopedic exam, the patient was removed from the ofﬁce by
emergency rescue and admitted to the hospital directly, where he
was treated once again for encephalopathy and ultimately
released.n of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-ND
Figure 1. Pre-operative radiographs at initial presentation demonstrating prior left TKA.
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internist and gastroenterologist. Records revealed a diagnosis of
Hepatitis C, Type 2b. Known co-morbidities included neutropenia,
anemia, thrombocytopenia, and cirrhosis with established portal
hypertension. A prior transjugular intrahepatic portosystemic
shunt (TIPS) procedure had already been performed to help stabi-
lize his cirrhosis.
RNA Viral load three years prior to his presentation above was
196552 IU/mL (reference 0e615 IU/mL) and both Hepatitis A and B
testing were non-reactive. His MELD score at that time was 10.
Albumin was 2.8 G/dL (Ref Range: 3.5e5.5 G/dL) and total protein
was 7.4 G/dL (Ref Range: 6e8.3 G/dL).Within a year of presentation,
records revealed his MELD score had climbed to 15, with an RNA
viral load of 560431 IU/mL. Three months prior to presentation, his
ammonia level was 108 ug/mL (reference 17e80 ug/mL), and the
albumin had improved to 3.1 G/dL.
After the patient's encephalopathy was clinically stabilized he
expressed a clear desire to seek treatment for his left knee, and then
underwent further preoperative testing with the support of his
medical physicians. It was felt that he was optimized to the best
degree achievable at that time, and that the potential beneﬁt of
revisionTKA for this patient outweighed the risks for complications.
Scintigraphic testing with a 3-phase bone scan was conducted
(Fig. 2), revealing increased activity at the left knee on all three
phases. Delayed images showed diffuse, marked uptake on both
sides of the left knee joint suspicious for a prosthesis infection. A
radio labeled Indium WBC scan (Fig. 3) demonstrated an area of
focal uptake on the medial left knee without concordant uptake on
the bone marrow scan, therefore suspicious for infection. Preop-
erative labs revealed an ESR of 52, and INR of 1.5, and a CBC showed
a WBC of 2.8, hemoglobin 8.8, and platelets of 96k.
Intraoperative ﬁndings revealed diffuse thickening of the
synoviumwith no purulence, and gross loosening of the femur andtibial components of the TKA. The failed rotating-platform TKAwas
then revised in a single-stage fashion. Cemented stems with metal
component augmentation was used with retention of the well-
ﬁxed patellar resurfacing button, and a constrained implant
design (Triathalon TS, Stryker Corporation, Kalamazoo, MI, USA)
was selected given his signiﬁcant intra-operative periarticular tis-
sue laxity (Fig. 4) Intraoperative frozen sections revealed an average
of 2 neutrophils per high power ﬁeld. Cultures of joint ﬂuid, and two
tissue cultures showed no bacteria on any gram stains or ﬁnal cul-
tures, and both fungal and AFB stains and cultures were also
negative.
Postoperatively, the patient was given a compressive dressing
with a knee immobilizer for two weeks while being allowed to
weight bear as tolerated on the left lower extremity. DVT prophy-
laxis with Lovenox 40 mg SC Daily was initiated andmaintained for
4 weeks, and his Aspirin 81 mg daily dose was continued
throughout. The patient healed uneventfully in the early phase of
recovery. At the time of this report, he is now 2 years and 6 months
postop. He has regained the ability to walk and continues to use a
cane for balance. ROM of the left knee is from 0 to 120 with stable
collateral exam and smooth patellar tracking. He reports inter-
mittent fatigue and is intermittently somnolent, but is able to
complete all ADL's and continues to be independent at baseline. No
further viral load testing is available at this time.
Discussion
Epidemiology
Chronic infectious liver conditions span a diverse set of patients
stemming from multi-faceted modes of transmission. Such modes
result in new infections across all age groups. Since the broad
adaptation of the hepatitis B vaccine into medical practice, the
Figure 2. Tc-99m MDP three-phase bone scan. Study demonstrated mildly increased ﬂow to the left knee. On the tissue phase, there was increased activity surrounding both sides
of the left knee joint, more prominent on the femoral side. On delayed imaging, there was diffuse, marked increased uptake on both sides of the left knee joint suggestive of
prosthesis infection.
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groups [6]. However, a signiﬁcant population still exists with
chronic HBV infections, amounting to ~800,000 people in the
United States [7]. Most infections take place via sexual transmission
and blood borne routes.
For hepatitis C, the Center for Disease Control (CDC) recently
reported that the highest incidence of new infections occurred in
patients between 20 and 29 years of age in 2012 (2 reported per
100,000 population). Patients aged 50 to 59 were found to have an
increasing incidence between 2010 and 2013 from 0.2 per 100,000
to 0.35 per 100,000 [6]. This population segment is coincident with
the patient group now most commonly seeking total joint arthro-
plasty in the United States, prompting the need for surgeon
awareness of this topic. Furthermore, 60% of hepatitis trans-
missions took place in the setting of intravenous drug use, 10%
secondary to transfusions, 15% were sexually transmitted, and 5% of
infections were seen in hemodialysis and healthcare workers sec-
ondary to needle sticks [8]. A total of approximately 4 million
persons in the United States are now living with chronic hepatitis C
virus, representing 1.5% of the 320.7 million people currently living
in the US [9].
Natural history of chronic infectious liver disease
Hepatitis C
Prior to 1990, before routine screening of donated blood for
HCV, patients at highest risk for acquiring acute hepatitis Cincluded those who received blood transfusions, blood products or
anti-D immunoglobulin in pregnancy, intravenous drug users,
tattoo or body piercing recipients under unsterile conditions, heath
care workers, dialysis patients, and those partaking in “high risk”
sexual activities [1]. After the introduction of routine screening of
blood products, the demographic proﬁle of newly infected patients
changed to predominantly those who use intravenous drugs and
homosexual men [10]. For those who are infected, the acute phase
is often unrecognized, as patients are typically asymptomatic or
have mild, viral ﬂu-like complaints. The rate of clearance of the
hepatitis C virus in the acute phase is reported to be roughly
15e40% [1,11].
The evolution of liver cirrhosis secondary to chronic HCV
infection has been reported to be 10e20% over the course of
20e30 years [12,13]. Co-infection with hepatitis B and HIV, given
the shared route of transmission for these diseases is common and
puts the patient at a higher risk for progression to liver cirrhosis
and the associated development of hepatocellular carcinoma
(HCC) [14,15]. Treatment of patients with anti-viral medications
(such as interferon-alpha, sofosbuvir, and simeprevir) has
demonstrated signiﬁcant improvements in necro-inﬂammation
and ﬁbrosis scores that correlate with improved surgical
outcomes [16,17].
Hepatitis B
Infection by the hepatitis B virus shares a similar etiology as
hepatitis C; however, the majority of the infected hepatitis B
Figure 3. Indium WBC scan. Study demonstrated focus of mild increased white blood cell uptake located at the medial femoral component of the left total knee arthroplasty
without concordant uptake on the bone marrow scan. This was found to correspond with the site of the most prominent increased uptake on the 3-phase bone scan consistent for
prosthesis infection.
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the patients go on to have persistent infection [18e20]. Of the
cohort that continues on to develop chronic HBV infection, roughly
20% eventually develop liver cirrhosis. Factors such as HIV and HCV
co-infection and chronic alcohol intake have been linked to the
incidence of liver cirrhosis [20]. Similar trends were seen when
evaluating the development of HCC in patients with hepatitis B
with the annual incidence of HCC estimated be at 2e3% in patients
with chronic hepatitis B [21].
Anti-viral therapies aimed at reducing viral loads have shown to
signiﬁcantly reduce necroinﬂammation and ﬁbrosis leading to
cirrhosis. This has resulted in a signiﬁcantly higher portion of pa-
tients who do not progress onto cirrhosis or developing HCC
[22,23].Extrahepatic manifestation of chronic infectious liver disease
In addition to intrahepatic manifestations, numerous extra-
hepatic presentations can manifest in chronic liver disease pa-
tients [24,25]. Manifestations can affect numerous organ
systems, including hematologic, dermatologic, renal, endocrine,
ocular, vascular, neuromuscular, and neuropsychiatric [26]. A
signiﬁcant portion of these ﬁndings are immune related. Mixed
cryoglobulinemia vasculitis is a small vessel vasculitis that
presents with damage to multiple end organs. The skin is
affected most frequently in the form of palpable purpura and
chronic cutaneous ulcers. Neuropathies are often encountered,
as well as, membranoproliferative glomerulonephritis related
nephropathy [26]. Some studies have noted the conversion of
the relatively benign vasculitis to a more malignant lympho-
proliferative state, particularly, B-cell non-Hodgkin lymphoma
[27]. Cardiovascular disease in the form of coronary athero-
sclerosis and carotid plaques have been implicated with chronic
hepatitis [24,28]. Though the etiology is unclear, an increased
association of insulin-resistant diabetes mellitus has beenreported. Cacaoub et al., reported that 38% of the patients
included in their analysis manifested at least 1 extrahepatic
ﬁnding, with a preponderance of rheumatic (19%) in the form of
arthralgia, myalgia and Sicca syndrome and cutaneous symp-
toms (17%) [24,26,29].
Effects of subclinical hepatitis
Observable clinical symptoms do not always portray the true
extent of disease in chronic infectious liver disease patients. Studies
have shown that numerous subclinical changes occur leading to
important changes in physiology even in the asymptomatic patient
(Table 1). Pour et al. investigated patients with non-cirrhotic hep-
atitis C (n ¼ 71) undergoing TJA [30]. All of the patients underwent
either total knee arthroplasty (TKA) or total hip arthroplasty (THA)
and had no signs of active infection, deﬁned as normal liver en-
zymes and no signs of cirrhosis. Compared to the control group
(n ¼ 150) increased surgical complications were noted in sero-
positive asymptomatic patients including longer hospital stays (5.2
days vs. 3.5 days, p ¼ .006), and higher reoperation rates (15% vs.
4.2%, p ¼ .004).
Similar ﬁndings were found in a recent article across a national
database for increased medical complications in asymptomatic
hepatitis C seropositive patients undergoing a TJA [31]. Compared
to a control group, patients with hepatitis C were twice as likely to
suffer a medical complication including the need for a blood
transfusion, post-transfusion anemia, acute renal failure, cardiac-
related complication, and pneumonia. A multivariable regression
analysis showed that the odds ratio for the occurrence of a medical
complication in a patient with hepatitis C (OR 2.102) undergoing a
total hip or knee arthroplasty was higher than a similar patient
with atrial ﬁbrillation (OR 1.844), diabetes mellitus (OR 0.937) or an
oldmyocardial infarction (OR 0.877), andwas comparable to having
congestive heart failure (OR 2.108). Also, when matched to the
seronegative controls, the asymptomatic hepatitis C cohort without
cirrhosis had nearly 4 times the odds of developing a pulmonary
Figure 4. Post-operative left TKA revision radiographs.
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following total joint arthroplasty.
A recent study of the NIS database further supported such
ﬁndings across a general population of patients infected with
hepatitis C. First, the study acknowledged that the percentage of
patients infected with hepatitis C receiving TKAs increased from
0.18% to 0.5% between 1998 and 2010. Expectedly, hepatitis C
infected patients (n ¼ 23,338) were found to be younger (67 vs.
58 yrs) and had a higher rate of surgical indication related to
osteonecrosis (0.7 vs. 1.6%, p < .0001). Hepatitis C infection in the
context of TKA carried a 1.34 higher odds ratio of perioperative
complications including pulmonary embolism, implant infection,
deep venous thrombosis and wound related complications.
Following the trend of TJA in general, both groups, however, had
shorter length of stays at the end of the studied period, but was
lower in the hepatitis population (4 vs. 3.75 days) [32].
Studies have shown that although the asymptomatic, seropos-
itive patient may have normal liver enzymes, the presence of au-
toantibodies, cryoglobulins and impaired lymphoproliferation may
explain the observed differences in this patient population. These
changes may also play an indirect role in wound healing, hemo-
dynamics, infection rates and medical stability [25,33].Table 1
Important subclinical changes in the chronic infectious liver disease patient.
Autoantibodies
Cryoglobulins
Lymphoproliferation
Thrombocytopenia
Impaired platelet functionAdditionally, it is well known that even in the absence of
cirrhosis, patients may have impaired platelet function and
thrombocytopenia [34,35]. Pour et al. recognized the possible
contribution of impaired platelet function when noting increased
wound drainage following total hip arthroplasty, but not following
TKA in patients with asymptomatic hepatitis C compared to the
control group [30]. This difference seen between the hip and knee
patients was postulated to be secondary to the use of a tourniquet
in the total knee population leading to extrinsic small arterial and
capillary hemostasis.Effects of cirrhotic hepatitis
Historically, chronic liver disease has been associated with
higher rates of surgical morbidity and mortality. Numerous studies
have reported perioperative mortality rates as high as 25% in non-
orthopedic procedures [36,37]. In addition to high mortality rates,
complications are not limited to increased bleeding, higher infec-
tion rates, renal insufﬁciency, encephalopathy, as well as multi-
system organ failure [38].
Shih et al., were one of ﬁrst groups to look at cirrhotic patients
undergoing total joint arthroplasty. They followed 51 patients
following TKA over an average of 42 months and compared how
they did to amatched cohort without liver cirrhosis [39]. Etiology of
cirrhosis in their group included hepatitis B, hepatitis C, and sec-
ondary to alcohol use. However, etiology speciﬁcally was not found
to be a contributing factor when evaluating outcomes. Cirrhotic
patients had statistically signiﬁcant higher rates of overall com-
plications (22/51 vs. 3/51, p < .001), higher mortality rates (15/42 vs.
Table 3
Positive predictive factors for reduced complication rates in patients undergoing TJA
with chronic infectious liver disease.
Young patients
Child class-A cirrhosis
MELD < 10
No history of hepatic decompensation
No history of variceal bleeding
Elective circumstances
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longer operative times (128 min vs. 102 min, p < .001). Observed
risk factors for increased complications included a history of he-
patic decompensation or variceal bleeding, attributing to a relative
risk increase of 3.3 compared to the control. Factors for infection,
the most common complication, included the above along with
increased age, and history of thrombocytopenia. Yet, despite the
higher complication rates, Child-Turcotte-Pugh (CTP) class-A
(Table 2) cirrhotic patients achieved good functional results in
71% of cases [40]. In light of the clinical improvement, the authors
felt that in selected patients, TKA was a safe and beneﬁcial
intervention.
Another recent investigation suggests that from 2000 to 2009 in
the United States there was a national volume increase of 182% and
304% for primary THA and TKA performed in patients also diag-
nosed with cirrhosis within the National Inpatient Sample. This
study may be the largest to date, and evaluated a total of 2.082
million THA and 4.475 million TKA patients and showed increased
risks for patients with cirrhosis following lower extremity arthro-
plasty, including longer LOS, increased cost, thrombocytopenia,
infection, acute renal failure, hemorrhage, stroke, and post-
operative blood transfusion. Patients with alcoholic cirrhosis had
the highest adjusted risk for thrombocytopenia (OR THA 14.54, TKA
19.45) compared with viral hepatitis (OR THA 3.99, TKA 3.76);
overall adjusted risk of all complications for patients with alcoholic
hepatitis was also higher (OR THA 2.23, TKA 2.58) than seen in
patients with viral hepatitis (OR THA 1.35, TKA 1.33) [41].
Expanding on earlier work, Orozco et al. focused more specif-
ically on the surgical impact of thrombocytopenia and ﬁbrosis in
patients with hepatitis C [42]. The retrospective study of 72 patients
found no signiﬁcant differences between patients with hepatitis C
and a control group in regards to length of stay, blood loss, or he-
moglobin drop following both THA and TKA. When a subset of
patients with clinical thrombocytopenia (<150,000/mL) was
examined, no statistically signiﬁcant differences were observed
across many outcomes including infection rate, reoperation rate,
requirement for irrigation and debridement, and hemoglobin drop.
Though not signiﬁcant, the results did show a trend toward
increased infection rate in the thrombocytopenic group (25% vs. 9%,
p ¼ .23), increased cellulitis or hematoma related admissions (12%
vs. 4%, p ¼ .40) and an increase in any adverse event (37% vs. 13%,
p ¼ .13). Unfortunately, as the authors attest, the study was simply
underpowered to reach any signiﬁcant conclusions regarding these
ﬁndings. The authors did ﬁnd signiﬁcant differences when isolating
patients with ﬁbrosis and comparing them to the group of hepatitis
C patients without ﬁbrosis. Statistically signiﬁcant increases in rates
of infection and admission for cellulitis and hematoma, as well as
greater hemoglobin dropswere observed in the groupwith ﬁbrosis.
These ﬁndings supported the viewpoint that ﬁbrosis is associated
with higher complication rates but failed to address the impact of
clinically signiﬁcant thrombocytopenia in patients with hepatitis C
undergoing TJA [37,42].Table 2
Child-Turcotte-Pugh (CTP) classiﬁcation system [42].
Parameter Points assigned
1 2 3
Ascites Absent Slight Moderate
Hepatic encephalopathy None Grade 1e2 Grade 3e4
Bilirubin (mg/dL) <2 2e3 3>
Prothrombin (INR) <1.7 1.7e2.3 >2.3
CPT classiﬁcation:
Child A: score 5e6 (well compensated)
Child B: score 7e9 (signiﬁcant functional compromise)
Child C: score 10e15 (decompensated)As shown by Cohen et al., surgical outcomes may also vary be-
tween patients undergoing elective and emergent TJA [43]. The
authors showed that in general, all cirrhotic patients when
matched to an equal control group, had longer operative times
(138 min vs. 93 min; p ¼ .0004), longer hospital stays (8.3 days vs.
5.1 days, p ¼ .0007) and an increased number of major periopera-
tive complications (6 vs. 3, p ¼ .006). However, when the elective
cases were separated from the emergent cases, substantial differ-
ences emerged. With the exception of hospital length of stay, (8.7
days vs. 4.7 days, p ¼ .0005) no signiﬁcant differences existed for
elective total hip arthroplasty in patients with cirrhosis and the
control group. In contrast, those undergoing emergent total hip
arthroplasty with a concurrent diagnosis of cirrhosis had statisti-
cally signiﬁcant higher rates of blood loss, operative time, hospital
days, major complications, liver decompensation and death
compared to the elective cases. These ﬁndings further support the
claim that recognition of risk factors and subsequent perioperative
optimization plays an important role in risk reduction for cirrhotic
patients undergoing TJA.Current controversies and future considerations
Currently, no formal guidelines exist for the treatment of pa-
tients with infectious chronic liver disease undergoing TJA. Despite
this, recommendations can be made to decrease the likelihood of
perioperative complications and optimize overall outcomes. First,
all patients should be screened for preoperative anemia and
thrombocytopenia. Second, all patients should be interviewed to
determine the etiology of the cirrhosis (if present), as alcoholic liver
disease may have a higher risk proﬁle than viral hepatitis cases
undergoing arthroplasty. Any known history of GI varices or acute
bleeding events, hepatocellular carcinoma, or hepatic encepha-
lopathy should be identiﬁed and considered as deﬁnite indicators
of more advanced liver disease.
In all cases, a complete and thorough discussion must be had
with the patient to emphasize the increased speculative riskFigure 5. Model for End Stage Liver Disease (MELD) score [43].
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tomatic patient with subclinical hepatitis. These risks may be
magniﬁed in patients undergoing THA as compared with TKA, but
caution is to be emphasized in all cases. A multi-disciplinary
approach is warranted, including preoperative consultations with
both an internist and hepatologist; consultation with a hematolo-
gist may be indicated when preparing for surgery to better address
the complex hemostasis issues that are unique to liver disease
patients. Given equivocal data regarding thrombocytopenia, func-
tional platelet testing may also be reasonable.
Patient selection is also an important component for improved
outcomes (Table 3). Potential risk factors including prior history of
hepatic decompensation, variceal bleeding, and cirrhosis, all of
which have been found to negatively impact outcomes, mandates
both a further discussion with the patient regarding expected
outcomes as well as adequate perioperative optimization. Stratiﬁ-
cations such as Child-Turcotte-Pugh scores andMELD scores (Fig. 5)
may provide objective data in which to educate the patient and co-
management teams [44,45]. For example, Tiberi et al., found that
MELD scores less than 10 were predictive of better outcomes in
patients undergoing TJA with liver cirrhosis. Especially, in cases of
elective surgical intervention, medical optimization such as viral
treatment to lower the overall burden of disease may improve the
long-term outcome. Unfortunately, newer therapies such as
Sofosbuvir may not be cost-effective. Moreover, the short-term or
long-term outcomes that accompany decreased viral loads has not
been vigorously tested [17]. A study on HIV patients undergoing TJA
found that a signiﬁcant drop in CD4 counts accompanied the
development of deep implant infections, but lower values did not
lead to increased rates [46]. This study suggests that change in viral
load and disease progression may be more important than absolute
viral load.
Summary
Fortunately for the many patients who suffer from mild to
moderate infectious chronic liver disease and degenerative joint
disease, the literature supports performing TJA for this popula-
tion despite an elevated potential for perioperative risk, espe-
cially under elective conditions in younger patients without a
history of hepatic decompensation, variceal bleeding, or ﬁbrosis
associated with liver cirrhosis. For patients with more severe liver
disease, including documented cirrhosis and varices, more sig-
niﬁcant caution is urged before considering TJA. This higher risk
population should be comprehensively evaluated by a multidis-
ciplinary team of specialists preoperatively, as complication rates
following TJA can rise dramatically and may negatively affect
outcomes.KEY POINTS
 TJA can be performed safely in patients with chronic infec-
tious liver disease when properly screened and medically
optimized.
 Subclinical changes in patients with chronic infectious liver
disease can lead to devastating complications.
 Risk factors for increased complications include older pa-
tients, MELD score >10, history of hepatic decompensation
and/or variceal bleeding, as well as emergent timing.
 MELD score should be considered in patients during initial
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